This study is performed on healthy volunteers..
Conditions
Interventions
Intervention 1: Intervention group: Single-dose of Valganciclovir 450 mg Tablets of The Test Drug (Actoverco Pharmaceutical Company), in the first period. Cross-over design with one week washing perio
Sponsors
?Actoverco Pharmaceutical Company
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: General health (liver, heart, kidney) of volunteers Body mass index range (18-30) Informed consent form Age between18-55
Exclusion criteria
Exclusion criteria: Smoking Pregnancy Having a hypersensitivity to the drug Having a Alcohol & Drug addiction Blood donation within the last 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The concentration of the drug in blood. Timepoint: 0-0.33-0.66-1-1.33-1.66-2-2.5-3-3.5-4-5-6-8-24 h after drug administration. Method of measurement: Liquid Chromatography with Mass-Mass Detector. | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to reach maximum blood concentration. Timepoint: After intervention. Method of measurement: The time to reach the maximum drug concentration in blood is recorded.;Extent of absorption. Timepoint: After intervention. Method of measurement: Calculation of area under curve of concentration -time. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMassoud Amanlou
Tehran University of Medical Sciences
Outcome results
None listed